CYTK · XBRL financial data

Cytokinetics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CYTK's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	0	2*	1	0	0	year only	2	67	2	18*	19	29
Research and development	83	85*	82	80	85	94*	100	113	99	104*	96	98
Selling, general and administrative	—	—	—	—	—	—	57	66	—	—	105	104
General and administrative	40	44*	46	51	57	62*	57	66	69	92*	—	—
Total operating expenses	123	129*	127	130	141	156*	157	178	169	196*	203	208
Operating income (loss)	(122)	(127)*	(126)	(130)	(141)	(139)*	(156)	(112)	(167)	(178)*	(184)	(179)
Interest expense	7	7*	7	13	9	9*	—	11	11	14*	—	—
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(129)	(137)*	(136)	(143)	(161)	(150)*	(161)	(134)	(306)	(183)*	(206)	(199)
Earnings per share, basic USD per share	(1.35)	—	(1.33)	(1.31)	(1.36)	—	(1.36)	(1.12)	(2.55)	—	(1.67)	(1.50)
Earnings per share, diluted USD per share	(1.35)	—	(1.33)	(1.31)	(1.36)	—	(1.36)	(1.12)	(2.55)	—	(1.67)	(1.50)
Weighted average shares, basic millions of shares	0	0*	0	0	0	0*	0	0	0	0*	0	0
Weighted average shares, diluted millions of shares	0	0*	0	0	0	0*	0	0	0	0*	0	0

Balance sheet

CSV

Fiscal quarters (CYTK's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	100	113	120	190	47	95	74	75	225	123	130	255
Marketable securities	440	502	499	867	965	981	865	783	737	760	689	910
Marketable securities, non-current	15	41	15	305	269	145	151	178	289	335	255	538
Accounts receivable	2	1	1	0	0	17	2	8	2	18	7	24
Inventory	—	—	—	—	—	—	—	—	—	0	0	0
Prepaid and other current assets	20	12	19	11	7	15	16	20	13	17	14	18
Total current assets	561	628	639	1,068	1,019	1,108	956	887	977	917	839	1,208
Property and equipment, net	76	69	68	66	64	66	67	70	76	79	82	79
Right-of-use asset	80	79	78	77	76	75	77	76	78	76	75	73
Total assets	741	824	808	1,524	1,436	1,402	1,264	1,226	1,437	1,425	1,273	1,925
Accounts payable	14	22	13	9	12	20	14	16	22	22	25	21
Accrued liabilities	33	43	40	40	50	55	43	52	62	83	69	77
Current portion of long-term debt	—	10	12	12	12	12	13	14	17	41	45	27
Total current liabilities	78	103	89	103	110	180	160	131	142	202	199	181
Long-term debt	61	58	57	93	93	93	92	159	159	246	247	248
Lease liability, non-current	122	120	119	117	115	113	113	111	111	108	105	102
Total liabilities	1,179	1,211	1,204	1,415	1,450	1,537	1,530	1,594	1,958	2,084	2,100	2,098
Accumulated deficit	(1,975)	(2,112)	(2,248)	(2,391)	(2,552)	(2,702)	(2,863)	(2,998)	(3,304)	(3,487)	(3,693)	(3,892)
Total stockholders' equity	(439)	(386)	(396)	109	(14)	(135)	(266)	(369)	(521)	(660)	(827)	(173)
Total liabilities and equity	741	824	808	1,524	1,436	1,402	1,264	1,226	1,437	1,425	1,273	1,925
Common shares outstanding (cover page) millions of shares	98	103	105	118	118	118	119	120	122	123	124	139

Cash flows

CSV

Fiscal quarters (CYTK's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(129)	(137)*	(136)	(143)	(161)	(150)*	(161)	(134)	(306)	(183)*	(206)	(199)
Stock-based compensation	19*	19*	22	25*	25*	26*	24	28*	31*	31*	30	36*
Depreciation and amortization	2*	6*	2	2*	2*	2*	2	2*	3*	3*	3	4*
Net cash from operating activities	(96)*	(74)*	(130)	(99)*	(102)*	(66)*	(132)	(128)*	(108)*	(143)*	(145)	(160)*
Purchases of property and equipment	0*	0*	0	2*	1*	1*	6	4*	9*	6*	6	4*
Net cash from investing activities	73*	(81)*	33	(652)*	(45)*	111*	106	53*	(71)*	(71)*	145	(507)*
Proceeds from issuing common stock	—	163*	94	—	—	—	0	0*	—	—	—	—
Repayments of long-term debt	0*	0*	1	3*	3*	3*	3	3*	3*	3*	3	4*
Net cash from financing activities	54*	169*	104	821*	3*	2*	5	79*	330*	111*	8	793*
Net change in cash	31*	13*	7	70*	(143)*	48*	(21)	2*	152*	(103)*	7	125*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Cytokinetics	255	29	(160)*	139.0M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Summit Therapeutics	419	not reported	(141)*	797.7M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Protagonist Therapeutics	420	213	219*	64.7M	—	Q2 FY26 10-QJun 30, 2026
Prestige Consumer Healthcare	89	266	71	47.4M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.